Cellceutix Files Motion to Dismiss Complaint Filed by The

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellceutix Files Motion to Dismiss Complaint Filed by The Rosen Law Firm

BEVERLY, MA --(Marketwired - February 12, 2016) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announces that the Company's counsel, The Ashcroft Law Firm, on Wednesday, February 10, 2016 submitted to the United States District Court, Southern District of New York, a Memorandum of Law in support of our Motion to Dismiss the Second Amended Complaint filed by The Rosen Law Firm, lead counsel to the only plaintiff in the case, Greg Zagami (as told to the court in December 2015). 

The document can be viewed at:

http://cellceutix.com/wp-content/uploads/2015...ss-SAC.pdf

The Request For Judicial Notice can be found at:

http://cellceutix.com/wp-content/uploads/2015...Notice.pdf

As Cellceutix has previously stated, the Company considers this case to be extremely frivolous and believe the facts in the Memorandum of Law prove this contention. Cellceutix wants to better clarify how a motion to dismiss works. At this point in a case, a judge essentially accepts everything in the (Plaintiff's) complaint as true. While the Company would like to say, "That allegation is factually not true" and provide reasons why, that is not how it's done in a Motion to Dismiss. As the defendant, Cellceutix is tasked with providing facts that the Company and its officers did not do anything improper with respect to disclosing information, disclaimers, scienter or any other of the allegations. The Company is limited in what exhibits may be used to plead its case, primarily kept to only regulatory filings and other documents the plaintiff referenced.

Cellceutix believes that the Ashcroft Law Firm clearly and effectively conveyed the message in the Memorandum of Law and Motion to Dismiss. Cellceutix's lead counsel, Mike Sullivan, addressed each allegation, systematically dismantling the complaint with legal precedent as to why the plaintiff's allegations are insufficient, that Cellceutix and its officers did not make any false or misleading statements and that the allegations do not state a claim.

In short, it is Cellceutix's contention that there are no legal grounds for the complaint and that The Rosen Law Firm has not provided factual allegations that are sufficient for the complaint to survive dismissal. As Mike Sullivan puts it, they are only trying to "create smoke."

Additional background material can be viewed at:

"Cellceutix Responds to Rosen Law Firm"

http://cellceutix.com/cellceutix-responds-to-...Aedgg.dpbs

Boston Business Journal

"My Visit To Cellceutix, The Biotech That A Short Seller Recently Called A Sham"

http://www.bizjournals.com/boston/blog/biofla...ml?ana=twt

The Rosen Law Firm press releases

http://www.businesswire.com/portal/site/home/...archPage=1 (It's necessary to scroll down past all the other releases Rosen files to August 6, 2015 and September 11, 2015 to view press releases regarding Cellceutix).

Other

The true Cellceutix. This week Cellceutix announced two important events. Regular updates will be forthcoming.

Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer

http://cellceutix.com/cellceutix-meets-with-f...4ZA0R.dpbs

Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI

http://cellceutix.com/cellceutix-to-submit-sp...or-absssi/ - sthash.uUkQhEWL.dpbs

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is concluding a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its application for a Phase 2 study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 32

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 24

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 56

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 44

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 136

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 106

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 20

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 41

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL NXTPAPER 70 Pro: Pioneering Eye-Care Technology Innovation

Updated Category News Views 159

TCL NXTPAPER 70 Pro Takes Center Stage at Award Ceremony TCL, a renowned name in the display technology sector, has recently celebrated a significant achievement. The TCL NXTPAPER 70 Pro smartphone has been awarded the esteemed Eye-Care Display Technology Gold Award during a prestigious ceremony. This momentous occasion unfolded at the renowned Global Top Brands Awards...

Continue Reading
Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans

Updated Category News Views 97

Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans Sky Quarry Inc. (NASDAQ: SKYQ) is making significant strides toward enhancing the waste-to-energy industry with its innovative Waste Asphalt Shingle Modular Facility. Situated in Woods Cross, Utah, this facility is currently at an impressive stage of completion, standing at 80%. This marks a pivotal moment for...

Continue Reading
Bell Canada’s Strategic Move to Redeem Debentures Early

Updated Category News Views 322

Bell Canada Announces Early Redemption of Debentures Bell Canada recently made an important announcement regarding its financial strategies that speak volumes about its commitment to prudent management. The company revealed plans to redeem its outstanding Cdn $750 million principal amount of 3.55% Debentures, Series M-41, before their maturity date. This redemption is set...

Continue Reading
Exciting Housing Announcement: Key Insights for Communities

Updated Category News Views 174

Anticipating New Housing Developments Media outlets are set to cover an important housing announcement with significant implications for local communities. This event highlights the collaboration between government officials and community leaders focused on addressing housing needs and enhancing infrastructure in various regions. Key Officials Present at the Event The...

Continue Reading
Innovative Partnership Aims at Transforming Material Research

Updated Category News Views 284

Exciting Collaboration to Enhance Material Research In a groundbreaking partnership, CAS, a division of the American Chemical Society, has joined forces with PetroChina Shanghai Advanced Materials Research Institute Co., Ltd. This collaboration aims to utilize the CAS SciFinder Discovery Platform™ to expedite the research and development of advanced chemical materials....

Continue Reading